Irinotecan Sun

Irinotecan, the active ingredient in Irinotecan Sun, is a topoisomerase I inhibitor presented as an injectable formulation for intravenous use. It is employed in the treatment of metastatic colorectal cancer and as adjuvant therapy for colon cancer in adult patients, interfering with DNA replication to induce tumor cell death under oncology specialist supervision.

GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, cancer treatment facilities and pharmacy networks worldwide.

Irinotecan is used in oncology to treat cancers that involve the colorectal pathway.

- Metastatic colorectal cancer: reduces tumor growth and extends survival in patients with advanced disease. - Adjuvant treatment of colon cancer: helps eradicate microscopic disease after surgical resection to lower recurrence risk.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Neutropenia: decreased white blood cells increasing infection risk. - Fatigue: general tiredness affecting daily activities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis or intestinal perforation: life‑threatening bowel complications. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes indicating liver injury.

Prior to initiating Irinotecan therapy, clinicians should observe several safety measures.

- Baseline blood counts: assess neutrophil and platelet levels before each cycle. - Liver function monitoring: evaluate transaminases and bilirubin regularly. - Bowel obstruction assessment: screen for pre‑existing gastrointestinal blockage. - Dose adjustment in renal impairment: modify regimen based on creatinine clearance. - Concomitant UGT1A1 genotype testing: consider reduced dosing for patients with deficient metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with other medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower drug exposure. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): increase risk of severe neutropenia and diarrhea. - Anticholinergic agents (e.g., atropine, scopolamine): heighten risk of ileus and bowel complications.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect serotonin pathways and require dose adjustment. - Anticoagulants (e.g., warfarin): increased bleeding risk due to potential platelet suppression.